54 results about "Vaginal atrophy" patented technology

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and / or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain / penetration disorders; vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest / arousal disorder, low female libido, and female orgasmic disorder.

The present invention relates to a composition for intravaginal and / or for internal mucosal application, comprising an effective amount of a sulfated polysaccharide, one or more of a natural quaternary polymer, a quaternary molecular compound, a metalloproteinase inhibitor, one or more anti-inflammatory agent, an acid pH control buffering system or any combination thereof, and a pharmaceutically acceptable carrier. The invention is further related to a method of treating or alleviating vaginal infection, vaginal dryness, vaginal or vulvo vaginal atrophy, vaginal itching, dyspareunia, vaginal or vulvar pain, vaginal or perivaginal inflammation or for promoting vaginal or wound healing, vaginal atrophy / dryness caused by radiotherapy, chemotherapy and / or hormonal treatment and decreased vaginal boundary lubrication or a disease or condition associated therewith or of improving vaginal boundary lubrication.

The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and / or the treatment of urogenital atrophy in women said women having a high probability of suffering from a cardiovascular pathology or suffering or having suffered from a cardiovascular pathology.